Artificial Intelligence-based Measurement of NASH Histology (AIM-NASH) recapitulates primary results from Phase 3 study of resmetirom for treatment of NASH/MASH with liver fibrosis

Conference Reports for NATAP

AASLD
The Liver Meeting
November Fri, Nov 10, 2023 - Mon, Nov 14, 2023


Artificial Intelligence-based Measurement of NASH Histology (AIM-NASH) recapitulates primary results from Phase 3 study of resmetirom for treatment of NASH/MASH with liver fibrosis

	AASLD 2023 nov 10-14 https://www.aasld.org/the-liver-meeting in MAESTRO-NASH a Phase 3 52-week serial Liver Biopsy Study in 966 patients with NASH treated with Resmetirom or Placebo